Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia (serum potassium < 3.5 mEq/L). * Prevention of hypokalemia in patients at risk (e.g., those on diuretics). ## Adult Dosing * **Oral Replacement:** * For **mild hypokalemia** (3.0-3.4 mEq/L): 20 mEq daily, divided into 1-2 doses. * For **moderate hypokalemia** (2.5-2.9 mEq/L): 40 mEq daily, divided into 2-4 doses. * For **severe hypokalemia** (< 2.5 mEq/L): May require higher doses, often initiated at 40-100 mEq daily, divided into 4-10 doses, with frequent serum potassium monitoring. * **Maximum oral dose:** Generally considered 200 mEq per 24 hours, but therapeutic need may dictate higher doses under close monitoring. * **Intravenous (IV) Replacement:** * Administer in a peripheral IV line or central venous access. * **Maximum infusion rate:** * **Peripheral line:** Typically 10 mEq/hour (20 mEq/hour in emergencies with cardiac monitoring). * **Central line:** Can be higher, up to 20-40 mEq/hour, with continuous cardiac monitoring. * **Concentration:** Do not exceed 40 mEq per liter (mEq/L) in peripheral lines to minimize phlebitis; higher concentrations are permissible in central lines. * **Dose:** Depends on severity of hypokalemia and patient's condition. Doses of 10-40 mEq may be given as a bolus or over 1-3 hours, with subsequent doses based on serum potassium levels. Total daily doses typically range from 40-120 mEq, but can be higher in severe cases. Local protocol often guides specific IV dosing strategies. ## Pediatric Dosing * **Oral Replacement:** * Recommended daily maintenance: 2-3 mEq/kg/day, not to exceed adult maximums. * For **treatment of hypokalemia**: Doses vary widely based on age, weight, and severity of deficit. Dosing should be guided by institutional protocols and pediatric nephrology/critical care expertise. * **Intravenous (IV) Replacement:** * **Maximum infusion rate:** Generally 0.3-0.5 mEq/kg/hour, not to exceed 10-20 mEq/hour in neonates and infants, and 20-40 mEq/hour in older children and adolescents. * **Concentration:** Do not exceed 40 mEq/L in peripheral lines. * **Dosing:** Individualized based on serum potassium, clinical status, and presence of other electrolytes. Doses of 0.5-1 mEq/kg can be administered IV over 1-3 hours, with repeat doses as needed. Total daily doses typically range from 40-120 mEq/m²/day, but can be higher. Close monitoring is essential. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Monitor potassium levels closely. Dose reduction is often necessary. Avoid in severe renal impairment if possible. ## Contraindications * Hyperkalemia. * Conditions leading to increased potassium levels (e.g., untreated Addison's disease, severe renal impairment, crush injury, extensive tissue damage). * Certain medications that increase potassium (e.g., potassium-sparing diuretics, ACE inhibitors, ARBs, potassium supplements). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence. * **Serious:** Hyperkalemia (especially with rapid IV administration or in renal impairment), cardiac arrhythmias, cardiac arrest, ECG changes (peaked T waves, flattened P waves, prolonged PR interval, ST depression), hypotension (with rapid IV infusion). * **IV administration specific:** Phlebitis, pain at injection site, extravasation. ## Key Drug Interactions * **Potassium-sparing diuretics** (e.g., spironolactone, amiloride, triamterene): Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia. * **NSAIDs:** Can impair potassium excretion, increasing risk of hyperkalemia. * **Heparin and low molecular weight heparins:** Can inhibit aldosterone production, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can potentiate digoxin toxicity. ## Monitoring * **Serum potassium levels:** Frequently monitor (e.g., every 4-6 hours initially for IV, daily or as indicated for oral) until stable. * **Renal function:** Monitor BUN and creatinine. * **ECG:** Especially with IV administration, rapid correction, or in patients with cardiac disease. * **Signs and symptoms of hyperkalemia:** Muscle weakness, fatigue, paresthesias, bradycardia, hypotension. ## Clinical Pearls * Oral potassium chloride should be taken with food or meals to minimize gastrointestinal upset. * Liquid formulations may be preferred for pediatric patients or those with difficulty swallowing tablets. * Never administer undiluted IV potassium chloride. * Always have a cardiac monitor available when administering IV potassium, especially at higher rates or concentrations. * Rapid IV administration of potassium can be fatal. * Correction of hypokalemia should be done cautiously, aiming for a serum potassium of 4.0-4.5 mEq/L. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and institutional protocols for definitive patient care decisions.